Galera Therapeutics, Inc.
GRTXOTCHealthcare● Active
$0.09
$-0.00(-4.09%)
Market Cap$6678571
P/E Ratio—
52W High$0.15
52W Low$0.015
Galera Therapeutics, Inc. (GRTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GRTX · as of 2026-06-15
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.02B | $0.03B | $0.05B |
| G&A Expenses | $0.01B | $0.01B | $0.02B | $0.02B | $0.02B |
| Total Operating Expenses | $0.01B | $0.01B | $0.05B | $0.05B | $0.07B |
| Operating Income | ($0.01B) | ($0.02B) | ($0.05B) | ($0.05B) | ($0.07B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | $0.15B | ($0.02B) | ($0.06B) | ($0.06B) | ($0.08B) |
| Income Tax Expense | $0.00B | ($0.00B) | $0.00B | ($0.00B) | $0.01B |
| Net Income | $0.15B | ($0.02B) | ($0.06B) | ($0.06B) | ($0.08B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.51 | $-0.35 | $-1.33 | $-2.30 | $-3.40 |
| Wtd Avg Shares | 0.10B | 0.05B | 0.04B | 0.03B | 0.03B |
| EBITDA | ($0.01B) | ($0.02B) | ($0.07B) | ($0.05B) | ($0.07B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · B
Explore more Galera Therapeutics, Inc. data
About Galera Therapeutics, Inc. (GRTX) Income Statement
Galera Therapeutics, Inc. (GRTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GRTX reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of $0.15B — a net profit margin of —.
Frequently asked questions
GRTX · 4 questionsGalera Therapeutics, Inc. (GRTX) reported revenue of $0.00B for 2025, down —% year-over-year.
GRTX revenueGRTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15